ALX Oncology Holdings

General Information


We are a clinical stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Cancer cells leverage CD47, a cell surface protein, as a “don’t eat me” signal, to evade detection by the immune system. Our company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. 

Employees: 24
Founded: 2015
Contact Information
Address 866 Malcolm Road, Suite 100 Burlingame, CA 94010, US
Phone Number 650-466-7125
Web Address
View Prospectus: ALX Oncology Holdings
Financial Information
Market Cap $555.4mil
Revenues $4.4 mil (last 12 months)
Net Income $-25.6 mil (last 12 months)
IPO Profile
Symbol ALXO
Exchange NASDAQ
Shares (millions): 8.5
Price range $19.00 - $19.00
Est. $ Volume $161.5 mil
Manager / Joint Managers Jefferies/ Credit Suisse/ Piper Sandler/ Cantor
CO-Managers LifeSci Capital
Expected To Trade: 7/17/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change